According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...

A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...